相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania
G. Mikucionyte et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
Deanna J. Buehrle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa
Stephen B. Vickery et al.
PHARMACOTHERAPY (2016)
The increasing threat of Pseudomonas aeruginosa high-risk clones
Antonio Oliver et al.
DRUG RESISTANCE UPDATES (2015)
Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
Brian D. VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
W. A. Craig et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Oren Zusman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
David J. Farrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2013)
Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Phillip J. Bergen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Differing Effects of Combination Chemotherapy with Meropenem and Tobramycin on Cell Kill and Suppression of Resistance of Wild-Type Pseudomonas aeruginosa PAO1 and Its Isogenic MexAB Efflux Pump-Overexpressed Mutant
G. L. Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effectiveness and Safety of Colistin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections
M. Montero et al.
INFECTION (2009)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
分享论文
